FSTL3 and neoplasm: We hypothesized that FSTL3 overexpression contributes to immunotherapy resistance by altering the tumor microenvironment: promoting a more mesenchymal tumor phenotype, increasing fibrosis by promoting myCAF development, suppressing immunocyte infiltration, and promoting T cell exhaustion.